(MedPage Today) — The DESTINY-Breast11 (DB-11) and DESTINY-Breast05 (DB-05) trials, presented at the European Society for Medical Oncology (ESMO) congress, showed that the inclusion of neoadjuvant or adjuvant trastuzumab pathologic complete response…
Source link : https://www.medpagetoday.com/meetingcoverage/esmovideopearls/118444
Author :
Publish date : 2025-11-11 17:56:00
Copyright for syndicated content belongs to the linked Source.
